ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Enzon Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $-0.00 Mil.
Enzon Pharmaceuticals's quarterly Other Stockholders Equity increased from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then declined from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($-0.00 Mil).
Enzon Pharmaceuticals's annual Other Stockholders Equity increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).
The historical data trend for Enzon Pharmaceuticals's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Stockholders Equity | Get a 7-Day Free Trial | - | -40.46 | - | - | - |
Enzon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 11-04-2010
By guruek guruek • 11-15-2009
By gurufocus 10qk • 03-16-2011
By Sheila Dang Sheila Dang • 06-23-2015
By Marketwired Marketwired • 08-22-2020
By gurufocus • 02-13-2010
By Marketwired Marketwired • 08-15-2020
By Marketwired Marketwired • 10-22-2020
By gurufocus Todd Sullivan • 03-14-2008
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.